D-631-2013 Class III Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-631-2013 was initiated by Pfizer Inc. on May 31, 2013 and is designated Class III. Reason for recall: Failed Dissolution Specifications: Pfizer Inc. (Pfizer) is recalling PREMPRO (conjugated estrogens/medroxyprogesterone acetate tablets) because certain lots for this product may not meet the… The recall status is terminated (terminated Apr 6, 2017). Affected quantity: 135,520 blister cards.

Recall details

Product Type
Drugs
Report Date
Jul 10, 2013
Initiation Date
May 31, 2013
Termination Date
Apr 6, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
135,520 blister cards

Product description

Prempro (Conjugated Estrogen/Medroxyprogesterone Acetate) tablets 0.625 mg/5.0 mg, 1 blister card containing 28 tablets, Rx only, Wyeth Pharmaceuticals Inc., Philadelphia, PA 1910, NDC 0046-0975-11

Reason for recall

Failed Dissolution Specifications: Pfizer Inc. (Pfizer) is recalling PREMPRO (conjugated estrogens/medroxyprogesterone acetate tablets) because certain lots for this product may not meet the specification for conjugated estrogens dissolution.

Distribution pattern

Nationwide and Puerto Rico

Code information

Lots: E77055, E96153, & F11111 Exp: 06/13

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-631-2013
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-631-2013. Report a data issue: hello@regdatalab.com.